XK
TVTX icon

Xact Kapitalforvaltning’s Travere Therapeutics TVTX Stock Holding History

Xact Kapitalforvaltning’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-8,795
Closed -$253K – 1524
2018
Q3 		$253K Hold
8,795
– – 0.01% 1457
2018
Q2 		$240K Sell
8,795
-400
-4% -$10.7K 0.01% 1478
2018
Q1 		$206K Buy
+9,195
New +$219K ﹤0.01% 1475

Other funds holding TVTX

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Xact Kapitalforvaltning's TVTX Position: Q4 2018 in Review

Xact Kapitalforvaltning sold out of Travere Therapeutics (TVTX) in Q4 2018, closing a stake of 8,795 shares — an estimated $253K sold.

Xact Kapitalforvaltning first reported a position in TVTX in Q1 2018 and held it in 3 quarters. The position peaked at $253K in Q3 2018. 130 funds tracked by Wall St. Rank hold TVTX as of Q4 2018.

  • Xact Kapitalforvaltning reported no remaining Travere Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Xact Kapitalforvaltning sold 8,795 Travere Therapeutics shares in Q4 2018, an estimated $253K.
  • Xact Kapitalforvaltning first reported a position in Travere Therapeutics in Q1 2018 and held it in 3 quarters.
  • Xact Kapitalforvaltning's Travere Therapeutics position peaked at $253K in Q3 2018.
  • 130 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2018.

Based on Xact Kapitalforvaltning's 13F filing for Q4 2018, filed 31 Jan 2019.